Literature DB >> 31339275

Infantile-onset Pompe disease: Diagnosis and management.

Luisa B Bay1, Inés Denzler2, Consuelo Durand3, Hernán Eiroa4, Joaquín Frabasil3, Alejandro Fainboim5, Clarisa Maxit2, Andrea Schenone3, Norma Spécola6.   

Abstract

Pompe disease, also known as acid maltase deficiency or glycogenosis type II, is a rare severe, autosomal, recessive, and progressive genetic disorder caused by deficiency in alpha-glucosidase. The classic infantile-onset is the most broadly known form of Pompe disease, which presents with severe heart involvement and clear hypotonia, while the non-classic presentation occurs with early motor involvement. Late-onset Pompe disease develops in adults, but it may also occur during childhood or adolescence. Here we update the available clinical and diagnostic findings because an early management with enzyme replacement therapy may improve patients' survival and quality of life. We also review the benefits and adverse effects of available treatments and new lines of therapeutic research. Sociedad Argentina de Pediatría.

Entities:  

Keywords:  Cardiomyopathies; Glycogenosis type II; Motor disorders; Muscular hypotonia; Pompe disease

Year:  2019        PMID: 31339275     DOI: 10.5546/aap.2019.eng.271

Source DB:  PubMed          Journal:  Arch Argent Pediatr        ISSN: 0325-0075            Impact factor:   0.635


  5 in total

1.  A Newborn with Infantile-Onset Pompe Disease Improving after Administration of Enzyme Replacement Therapy: Case Report.

Authors:  Meltem Bor; Ozkan Ilhan; Evren Gumus; Solmaz Ozkan; Meryem Karaca
Journal:  J Pediatr Intensive Care       Date:  2020-07-15

2.  Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases.

Authors:  Maria Paola Belfiore; Francesca Iacobellis; Emma Acampora; Martina Caiazza; Marta Rubino; Emanuele Monda; Maria Rosaria Magaldi; Antonietta Tarallo; Marcella Sasso; Valeria De Pasquale; Roberto Grassi; Salvatore Cappabianca; Paolo Calabrò; Simona Fecarotta; Salvatore Esposito; Giovanni Esposito; Antonio Pisani; Luigi Michele Pavone; Giancarlo Parenti; Giuseppe Limongelli
Journal:  PLoS One       Date:  2020-05-19       Impact factor: 3.240

Review 3.  Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes.

Authors:  Emanuele Monda; Marta Rubino; Michele Lioncino; Francesco Di Fraia; Roberta Pacileo; Federica Verrillo; Annapaola Cirillo; Martina Caiazza; Adelaide Fusco; Augusto Esposito; Fabio Fimiani; Giuseppe Palmiero; Giuseppe Pacileo; Paolo Calabrò; Maria Giovanna Russo; Giuseppe Limongelli
Journal:  Front Pediatr       Date:  2021-02-25       Impact factor: 3.569

4.  At-Risk Testing for Pompe Disease Using Dried Blood Spots: Lessons Learned for Newborn Screening.

Authors:  Zoltan Lukacs; Petra Oliva; Paulina Nieves Cobos; Jacob Scott; Thomas P Mechtler; David C Kasper
Journal:  Int J Neonatal Screen       Date:  2020-12-21

5.  Correlation of GAA Genotype and Acid-α-Glucosidase Enzyme Activity in Hungarian Patients with Pompe Disease.

Authors:  Aniko Gal; Zoltán Grosz; Beata Borsos; Ildikó Szatmari; Agnes Sebők; Laszló Jávor; Veronika Harmath; Katalin Szakszon; Livia Dezsi; Eniko Balku; Zita Jobbagy; Agnes Herczegfalvi; Zsuzsanna Almássy; Levente Kerényi; Maria Judit Molnar
Journal:  Life (Basel)       Date:  2021-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.